Table 2 Meta-analysis results of relationships between different antiviral strategies and mortality risks
 FNC vs No antiviral therapy | No. of cohorts | Effects model | I2 (%) | OR (95%CI) | P | Relationships | Publication bias (P value of Egger’s test) |
|---|---|---|---|---|---|---|---|
Overall patients | 7 | Fixed | 28 | 0.41 (0.31–0.54) | < 0.001 | Decreased risk | 0.20 |
Patients with mild to moderate COVID-19 | 3 | Fixed | 0 | 0.28 (0.13–0.58) | < 0.001 | Decreased risk | 0.52 |
Patients with severe COVID-19 | 5 | Fixed | 44 | 0.43 (0.30–0.63) | < 0.001 | Decreased risk | 0.22 |
Patients over 65 years old | 4 | Fixed | 30 | 0.48 (0.34–0.66) | < 0.001 | Decreased risk | 0.83 |
Patients with hypertension | 3 | Fixed | 0 | 0.64 (0.41-1.00) | 0.05 | No significance | 0.51 |
Patients with diabetes | 4 | Fixed | 0 | 0.67 (0.41–1.08) | 0.10 | No significance | 0.72 |
Patients with cardiovascular disease | 3 | Random | 57 | 0.46 (0.16–1.28) | 0.1 | No significance | < 0.001 |